4.5 Article

Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

Journal

BMC INFECTIOUS DISEASES
Volume 13, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2334-13-471

Keywords

HIV; Non-AIDS defining cancers; Incidence; Trends; Prognosis

Funding

  1. Highly Active Antiretroviral Therapy Oversight Committee (HAART-OC)
  2. Health Insurance Fund Council, Amstelveen, the Netherlands [CURE/97-46486]
  3. Agence Nationale de Recherches sur le SIDA [7]
  4. Foundation for AIDS Research, amfAR
  5. U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) [U01-AI069907]
  6. Merck Sharp Dohme
  7. Gilead Sciences
  8. Bristol-Myers Squibb
  9. Boehringer Ingelheim Pharmaceuticals Inc.
  10. Roche
  11. Pfizer
  12. GlaxoSmithKline
  13. Janssen Pharmaceuticals
  14. Australian Government Department of Health and Ageing
  15. Fondo de Investigacion Sanitaria [FIS 99/0887]
  16. Fundacion para la Investigacion y la Prevencion del SIDA en Espana [FIPSE 3171/00]
  17. National Institute of Allergy and Infectious Diseases, National Institutes of Health [5U01AI042170-10, 5U01AI046362-03]
  18. European Commission [CT94-1637, CT97-2713, QLK2-2000-00773]
  19. Abbott Laboratories
  20. Gilead Sciences Inc.
  21. Pfizer Inc.
  22. Swiss National Science Foundation

Ask authors/readers for more resources

Background: Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Methods: Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression. Results: Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort. Conclusions: The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available